Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial
--- Potential Risks and Considerations Because BPC-157 and TB-500 are not approved veterinary drugs, potential risks may include: Unknown long-term safety effects Variability in product quality or sterility Contamination risks with unregulated suppliers Potential interactions with other medications or supplements Owner supervision alone is not a substitute for veterinary guidance
Eur J Clin Pharmacol 80:1137 Yousra M, Elsherbiny NM, El-Shafey M, Said E (2020) The interplay of the inhibitory effect of nifuroxazide on NF-B/STAT3 signaling attenuates acetic acid-induced ulcerative colitis in rats
PMC 6430418
TB-500 (wound healing), but its also being used to reduce inflammation and injury recovery
More Information Press to skip carousel Recently Viewed Products The product was added to your cart